Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAS2R14 | Q9NYV8 | 1/20 | 0.42 |
| ▸ | P2RX7 | Q99572 | 6/20 | 0.41 |
| ▸ | CMA1 | P23946 | 4/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.39 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.39 |
| ▸ | SCN8A | Q9UQD0 | 1/20 | 0.38 |
| ▸ | IDO1 | P14902 | 2/20 | 0.38 |
| ▸ | CTSS | P25774 | 1/20 | 0.38 |
| ▸ | PIK3C2B | O00750 | 1/20 | 0.37 |
| ▸ | DHODH | Q02127 | 1/20 | 0.37 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL737569 | 0.85 | PDCD1 (0.48) | TAS2R14P2RX7CMA1CYP2D6SLC6A2 | |
| SCHEMBL10124833 | 0.81 | P2RX7 (0.39) | TAS2R14P2RX7CYP2D6SLC6A2SLC6A4 | |
| SCHEMBL15532671 | 0.81 | P2RX7 (0.41) | TAS2R14P2RX7CMA1CYP2D6SLC6A2 | |
| SCHEMBL18753207 | 0.79 | IDO1 (0.41) | TAS2R14P2RX7CMA1CYP2D6SLC6A2 | |
| SCHEMBL31751977 | 0.79 | GABRA1 (0.46) | TAS2R14P2RX7CYP2D6SLC6A2SLC6A4 | |
| SCHEMBL11967099 | 0.79 | GABRA1 (0.46) | TAS2R14P2RX7CYP2D6SLC6A2SLC6A4 | |
| SCHEMBL4550354 | 0.77 | MAOB (0.45) | TAS2R14P2RX7CYP2D6SLC6A2SLC6A4 | |
| SCHEMBL30513592 | 0.77 | P2RX7 (0.41) | TAS2R14P2RX7CMA1CYP2D6SLC6A2 | |
| SCHEMBL724189 | 0.77 | P2RX7 (0.41) | TAS2R14P2RX7CMA1CYP2D6SLC6A2 | |
| SCHEMBL17845893 | 0.77 | P2RX7 (0.42) | TAS2R14P2RX7CYP2D6SLC6A2SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2432321-B1 | THIAZOLOPYRIMIDINONE DERIVATIVES AS PI3 KINASE INHIBITORS | GLAXOSMITHKLINE LLC (US) | 2017-06-14 | — | — | EP | disclosed |
| US-8410095-B2 | Thiazolopyrimidinone derivatives as PI3 kinase inhibitors | GLAXOSMITHKLINE LLC (US) | 2013-04-02 | — | — | US | disclosed |
| US-8410095-B2 | Thiazolopyrimidinone derivatives as PI3 kinase inhibitors | GLAXOSMITHKLINE LLC (US) | 2013-04-02 | — | — | US | disclosed |
| EP-2432321-A1 | THIAZOLOPYRIMIDINONE DERIVATIVES AS PI3 KINASE INHIBITORS | GlaxoSmithKline LLC (US) | 2012-03-28 | — | — | EP | disclosed |
| US-20120053147-A1 | THIAZOLOPYRIMIDINONE DERIVATIVES AS PI3 KINASE INHIBITORS | GLAXOSMITHKLINE LLC | 2012-03-01 | — | — | US | disclosed |
| US-20120053147-A1 | THIAZOLOPYRIMIDINONE DERIVATIVES AS PI3 KINASE INHIBITORS | GLAXOSMITHKLINE LLC | 2012-03-01 | — | — | US | disclosed |
| WO-2010135504-A1 | THIAZOLOPYRIMIDINONE DERIVATIVES AS PI3 KINASE INHIBITORS | GLAXOSMITHKLINE LLC (US) | 2010-11-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120053147-A1 | THIAZOLOPYRIMIDINONE DERIVATIVES AS PI3 KINASE INHIBITORS | PIK3CD, PIK3CA, PI4KA | TAS2R14 3053/4885P2RX7 1747/4885CMA1 4569/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.